Financial Data and Key Metrics Changes - The company reported record quarterly revenue of $13.5 million for Q3 2025, a 29% increase compared to $10.5 million in the same period last year [5][15] - Gross profit for the quarter was $10.2 million, up from $7.7 million in the prior year, maintaining a gross margin of 75% [16] - Operating profit increased to approximately $1.3 million from $0.3 million year-over-year, with adjusted EBITDA rising to $2 million from $1.1 million [16][18] - The company ended the quarter with $70.7 million in cash and cash equivalents, an increase of $1.1 million from the previous year [17] Business Line Data and Key Metrics Changes - The company shipped 90 deep TMS systems during the quarter, representing a 43% increase year-over-year, bringing the total install base to over 1,600 systems [5][15] - Approximately 70% of recent customer engagements were structured as lease agreements, indicating a strong transition to this sales model [6][7] Market Data and Key Metrics Changes - Remaining performance obligations under existing customer agreements grew to $65 million, a 37% year-over-year increase, providing strong visibility into future revenues [17] - The company is seeing strong demand momentum, reflected in a book-to-bill ratio of 1.3x for the quarter [8] Company Strategy and Development Direction - The company focuses on three key pillars for long-term growth: elevating market awareness of deep TMS, advancing the R&D roadmap, and broadening patient access through global extension and health system integration [9] - Recent FDA approval for an accelerated treatment protocol for major depressive disorder (MDD) is expected to enhance the appeal of deep TMS to prospective patients [10] - The company is pursuing minority equity investments in mental health providers to generate shareholder value and expand market awareness [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing strong execution of the business model and improved visibility into the remainder of the year [5][6] - The company raised its revenue guidance for the full year 2025 to a range of $51 to $52 million, reflecting a year-over-year growth rate of 24% to 27% [18] Other Important Information - The company announced a virtual investor and analyst day on December 1 to discuss operational, clinical, regulatory, and financial progress [14] - The company remains debt-free, providing significant flexibility for strategic growth initiatives [17] Q&A Session Summary Question: Can you discuss the accelerated protocol and its current treatments? - The accelerated protocol shortens the acute phase from four weeks to six days, increasing treatment frequency to five sessions per day, which is driving demand for the company's growth [21] Question: What can be expected regarding minority equity investments? - The company has a pipeline of minority investments and aims to sign at least one more by the end of the year, with promising opportunities for 2026 [22] Question: Update on NeuroLife's activities in Japan and the EU? - The company anticipates FDA clearance for NeuroLife's device by the end of the year, which will enable distribution through various channels [23] Question: Insights on system placements from minority partners? - Minority investments are expected to lead to the opening of 10 to 15 new clinics annually, with early investments showing over 50% growth in utilization rates [28][29] Question: Plans for altering metrics reporting? - The company plans to provide more granularity on metrics, including system shipments and performance of minority investments, during the analyst day [35] Question: State of international business and growth expectations? - The company expects strong growth from Asia-Pacific and Europe, particularly in Japan, China, and major European markets [36][37]

Natural Gas Services Group (NYSE:NGS) Q3 2025 Earnings Call November 11, 2025 08:30 AM ET Speaker0Good morning, ladies and gentlemen, and welcome to the Natural Gas Services Group Incorporated Quarter Three Earnings Call. I would now like to turn the call over to Ms. Hannah Delgado. Please begin.Speaker1Thank you, Luke, and good morning, everyone. Before we begin, I would like to remind you that during the course of this conference call, the company will be making forward looking statements within the meani ...

ASM: TSX/NYSE American www.avino.com A Clear Path to Transformational Growth November 2025 Precious Metals Summit - Zurich A CLEAR PATH TO TRANSFORMATIONAL GROWTH The Avino Mine Property ASM: TSX/NYSE American www.avino.com A Clear Path to Transformational Growth 2 CAUTIONARY DISCLAIMER: FORWARD-LOOKING STATEMENTS This presentation contains "forward-looking information" and "forward-looking statements" (together, the "forward looking statements") within the meaning of applicable securities laws and the Unit ...

Ambac Financial Group (NYSE:AMBC) Q3 2025 Earnings Call November 11, 2025 08:30 AM ET Speaker3Ladies and gentlemen, good morning and welcome to the Octave Specialty Group's third quarter 2025 earnings call. At this time, all participants are in listen-only mode. A brief question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please signal the operator by pressing star zero on your telephone keypad. As a reminder, this conference is ...

Summary of Sierra Madre Gold and Silver Conference Call Company Overview - **Company**: Sierra Madre Gold and Silver (OTCPK:SMDR.F) - **Industry**: Mining, specifically silver and gold production - **Location**: Mexico - **Current Production**: Producing silver from La Guitarra mine, with quarterly production between 150,000 and 190,000 ounces since Q4 2024 [1][2] Key Highlights - **Production Achievement**: Successfully put the mine into production on time and on budget, marking a significant milestone for the company [2][6] - **Investor Support**: Welcomed notable investors including Eric Sprott and Fidelity, enhancing the company's financial backing [2] - **Expansion Plans**: Aiming to triple production over the next two years, with plans to increase production capacity from 500 tons per day to 1,500 tons per day [7][9] Financial Performance - **Revenue and Profit**: Generated $5 million in revenue and approximately $1.2 million in net profit in Q2, prior to a surge in silver prices [6] - **Production Costs**: Targeting production costs below $22 per ounce, with potential margins of around $30 per ounce if silver prices remain at $50 [8] Resource and Exploration - **Silver Resource**: Currently holds a resource of 50 million ounces of silver, with plans for 25,000 meters of drilling to increase this resource [5][11] - **Historic Mines**: The company operates in a historically significant silver and gold district with nine historic mines, including the recently opened Coloso and Nazareno mines [4][5] Future Projects - **El Rincón Mine**: Plans to drill at El Rincón, which historically produced silver at 800 grams per ton and gold at 6.5 grams per ton [9][10] - **Tepic Project**: A second project with a resource of about 10 million ounces of silver, but currently not the main focus due to the need for permits [11][14] Management and Ownership - **Management Team**: Includes experienced individuals with a history of successful mine operations in Mexico [3][4] - **Ownership Structure**: Management and founders retain 21% ownership, indicating strong alignment with long-term investor interests [12][13] Market Position - **Valuation**: The company is considered undervalued, with a market cap below CAD 200 million, presenting a potential investment opportunity [12][18] - **Investor Sentiment**: Despite recent market fluctuations, the company is viewed as a good entry point for investors [17][18] Additional Notes - **Permitting Status**: La Guitarra is fully permitted for underground operations, while Tepic requires further permitting [14] - **Support from First Majestic**: First Majestic has been supportive, providing loans and not selling shares on the market, which is seen as a positive for future capital [16][17]

Arcutis Biotherapeutics (NasdaqGS:ARQT) FY Conference November 11, 2025 08:30 AM ET Company ParticipantsFrank Watanabe - President, CEO, and DirectorLatha Vairavan - CFOConference Call ParticipantsSeamus Fernandez - Financial AnalystSeamus FernandezThe opportunity itself, you know, and the path towards that change in belief and conviction.Frank WatanabeSure. So good always to be here with you.Seamus FernandezYep.Frank WatanabeYou know, I think that what folks probably did not appreciate when we first starte ...

Solesence (NasdaqCM:SLSN) Q3 2025 Earnings Call November 11, 2025 08:30 AM ET Speaker1Good day, and thank you for standing by. Welcome to the Solesence Third Quarter 2025 conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To participate, you will need to press star 1-1 on your telephone. You will then hear a message advising your hand is raised. To withdraw your question, simply press star 1-1 again. We as ...

Sionna Therapeutics (NasdaqGM:SION) FY Conference November 11, 2025 08:30 AM ET Speaker3A different part of the protein, specifically NBD1, and I'm sure we'll get more into NBD1 and what its role in the biology is and how this is unique and different. Our goal really is to disrupt, in a positive way, the CF landscape. We think we have an opportunity to transform the treatment of patients and provide new options, potentially more efficacious options, with a goal of getting as many patients to normal CFTR fun ...

Edgewise Therapeutics (NasdaqGS:EWTX) FY Conference November 11, 2025 08:30 AM ET Company ParticipantsKevin Koch - CEOBehrad Derakhshan - COOConference Call ParticipantsDebjit Chattopadhyay - Senior Biotech AnalystDebjit ChattopadhyayGood morning. Thank you for joining Guggenheim's 2025 healthcare innovations conference. I am Debjit, one of the therapeutic analysts here, and my privilege to welcome our next presenting company, Edgewise Therapeutics. Joining from Edgewise are CEO Kevin Koch and Chief Operati ...

Ceragon Networks (NasdaqGS:CRNT) Q3 2025 Earnings Call November 11, 2025 08:30 AM ET Speaker2Ladies and gentlemen, thank you for standing by. Our call will begin shortly. Ladies and gentlemen, thank you for standing by. Our call will begin shortly. Ladies and gentlemen, thank you for standing by, and welcome to Ceragon Networks' third quarter 2025 earnings call. Our presentation today will be followed by a question-and-answer session, at which time, if you wish to ask a question, you will either need to rai ...